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Abstract: The combination of LC-MS/MS based metabolomics approach and anti-MRSA
activity-guided fractionation scheme was applied on the Gram-negative bacterium Aequorivita sp.
isolated from shallow Antarctic sea sediment using a miniaturized culture chip technique. This
methodology afforded the isolation of three new (1–3) and four known (4–7) N-terminal glycine- or
serine-bearing iso-fatty acid amides esterified with another iso-fatty acid through their C-3 hydroxy
groups. The chemical structures of the new compounds were elucidated using a set of spectroscopic
(NMR, [α]D and FT-IR) and spectrometric (HRMS, HRMS/MS) methods. The aminolipids possessing
an N-terminal glycine unit (1, 2, 4, 5) showed moderate in vitro antimicrobial activity against
MRSA (IC50 values 22–145 µg/mL). This is the first in-depth chemistry and biological activity
study performed on the microbial genus Aequorivita.
Keywords: Aequorivita; Gram-negative bacterium; miniaturized culture chip; linear aminolipid;
MRSA; LC-MS/MS
1. Introduction
The diversity of microbes on earth is enormous. However, despite all the progress made
in microbiology over more than 100 years, still only a little fraction (<1%) of microbial species
can be grown in artificial media. The remaining 99% remain resistant to standard cultivation
techniques, leading to the famous “dark matter” phenomenon in microbiology [1]. Cultivability
is not only a main issue in microbial ecology studies, but also the major obstacle in exploration
of bacteria for their bioactive constituents, e.g., for discovery of antibiotics. Several techniques,
such as diffusion chambers [2] or the iChip [3] have been used to increase microbial cultivability.
The iChip, a multichannel device consisting of hundreds of miniature diffusion chambers and
semipermeable membranes increases the cultivability rate up to 50% [3] as the device is placed
in the natural environment with all factors required for growth being present. The iChip has been
used to simultaneously isolate and grow uncultured bacteria, including the soil β-proteobacterium
Eleftheria terrae, which yielded teixobactin, a depsipeptide antibiotic inhibiting the cell wall synthesis
without detectable resistance [4]. A similar approach is the use of a Miniaturized Culture Chip
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(MCC) [5,6], which is also directly placed on natural sediments. The nutrients and signaling molecules
from the microbial community present in the sediment can diffuse into wells through a highly porous
ceramic membrane (which acts as a sterile filter), thus simulates a natural environment. This allows
microbes to grow in the microwells on the upper side of the chip as segregated microcolonies leading to
the isolation of previously uncultivated microorganisms. The MCC has two differences with the iChip
in design and use: (1) the cultivation wells are open allowing microscopy of the growing microcolonies
and therefore selection is possible based around phenotype and (2) the large number of wells (4000 to
hundreds of thousands) allow an inoculation strategy where only a fraction of the wells are occupied
by a growing colony, which is likely to be a single strain protected from antagonism by neighbours [6].
Gram-negative bacteria are a very large and taxonomically diverse group of microorganisms with
high survival and adaptation capability in every environment [7]. Although the current biodiscovery
studies mostly focus on Gram-positive Actinobacteria, Gram-negative bacteria are being increasingly
recognized as a prolific source of diverse molecules with wide ranging biological activities [7,8].
A prominent example of a molecule from this group of marine bacteria is didemnin B, the first marine
natural product that entered clinical trials against cancer. This compound, originally reported from
the Caribbean tunicate Trididemnum solidum was shown in 2011 to be produced by the Gram-negative
α-proteobacterium Tistrella mobillis [9]. Another eminent example is represented by the bryostatins,
complex polyketides that modulate protein kinase C. Bryostatins are potent anticancer and neurological
agents that have been linked to an as yet uncultured Gram-negative γ-proteobacterial symbiont of
the marine bryozoan Bugula neritina, Candidatus Endobugula sertula. A bryostatin polyketide synthase
gene cluster has been identified from Ca. E. sertula [10]. Several recent reviews have highlighted the
chemical diversity, bioactivity and biosynthetic machinery of the Gram-negative bacteria [7,11,12],
pointing out their untapped potential in discovery of new, bioactive molecules.
Aequorivita is a small genus of the Gram-negative bacterial family Flavobacteriaceae. This genus was
first discovered in 2002 from Antarctic habitats [13]. The existing studies on the few known members
of Aequorivita have only dealt with the taxonomy, fatty acid composition and DNA G+C content [13],
but no in-depth chemical or bioactivity study has been performed on any member of this genus so far.
By employing the MCC method, we have isolated from Antarctic shallow sea sediment an Aequorivita sp.
that showed moderate in vitro activity against MRSA. The combination of the traditional (MRSA)-activity
guided isolation scheme with LC-MS2-based metabolomics approach allowed the dereplication and
subsequent isolation of aminolipids from the bioactive fractions of this bacterium. The further purification
steps afforded three new (1–3) and four known (4–7) linear aminolipids that are glycine (Gly) or
glycyl-serine (Gly-Ser)-bearing iso-fatty acid amides esterified with another iso-fatty acid through their
C-3 hydroxy groups. Herein, we describe the details of LC-MS2-based metabolomics studies along with
the isolation, structural elucidation and the antimicrobial activity of compounds 1–7.
2. Results
The EtOAc extract of the bioactive pellet (anti-MRSA IC50 value 120 µg/mL) was fractionated
over a C18 SPE cartridge to yield six fractions. The activity was tracked to fractions 5 and 6, but due
to little amounts of fraction 5, only fraction 6 was studied by LC-MS/MS-based metabolomics
followed by purification studies. An in-depth manual dereplication of this fraction using multiple
commercial and public databases led to the annotation of four known aminolipids, two with N-terminal
glycine unit, i.e., compounds 4 (m/z [M + Na]+ 590.4759, C34H65NO5Na) and 5 (m/z [M + Na]+
588.4617, C34H63NO5Na), and two with N-terminal serine moiety, WB-3559 A (6, m/z [M + Na]+
661.4747, C36H66N2O7Na) and WB-3559 B (7, m/z [M + Na]+ 675.4936, C37H68N2O7Na) (Figure 1).
The HRMS2 fragmentation pattern was most helpful in rapid identification of the chain length and
unsaturation level of iso-fatty acyl moieties following the cleavage of the ester bond at C-3 (Figure S20).
The HRMS/MS spectrum of 4 showed a characteristic fragment ion at m/z [M + Na]+ 348.2568,
corresponding to the loss of 242 Da (C15H30O2). This led to the assignment of the (lower) fatty acyl
moiety as iso-pentadecanoic acid in 4. The HRMS2 spectra of the compounds 5, 6 and 7 contained
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fragments due to loss of 240 Da ([M + Na−C15H28O2]+), indicating the presence of a double bond. Thus,
the (lower) fatty acyl moiety was identified as iso-pentadecenoic acid in compounds 5–7. The additional
minor fragments observed at m/z 435.2878 in 6 and m/z 449.3053 in 7, correspond to the loss of 226 Da
([M−C7H11N2O5Na]+), confirming the amino acid residue as glycyl-serine. The combination of those
fragments permitted to determine, by deduction, the chain length of the upper fatty acid esterified at
(up to) C-3 as C14 and C15 in compounds 6 and 7, respectively.
Figure 1. Chemical structures of the aminolipids (1–7) isolated from Aequorivita sp.
As LC-MS2 analyses could not annotate several compounds in multiple databases, we decided to
undertake purification studies on the SPE fraction 6 to obtain potentially new metabolites. Repeated
RP-HPLC separation of this fraction afforded a new aminolipid (1) and two new methyl ester
derivatives (2 and 3), in addition to the four known metabolites described above, 4 [14–16], 5 [15],
WB-35559 A (6) [17,18] and WB-35559 B (7) [17,18] (Figure 1). The structures of the known compounds
were confirmed by comparison of their NMR, [α]D and LC-HRMS and MS/MS data with those
previously reported [14–18].
The new compound 1 was isolated as yellow oil with the molecular formula C33H63NO5 as
deduced by HRESIMS (m/z 576.4603, [M + Na]+). The 1H and 13C NMR data (Tables 1 and 2)
contained characteristic resonances of a linear N-terminal amino acid-bearing iso-fatty acid amide
esterified with another iso-fatty acid, including a glycine residue (δC 171.1, C-1′ ′; δH 4.07, H2-2′ ′, δC
41.1 C-2′ ′), an oxymethine (δH 5.16, δC 71.1, H-3), an amide carbonyl at δC 170.5 (C-1) and an ester
carbonyl at δC 173.7 (C-1′). Also evident were two sets of isopropyl termini (δH 0.86, d, J = 6.7 Hz,
12H, CH3-16, CH3-17, CH3-13′ and CH3-14′; 1.51, m, 2H, H-15 and H-12′) plus strongly overlapped
methylene signals around δH 1.25 (m) characteristic of (an) aliphatic fatty acid chain. Two complex
multiplets downshielded to δH 2.54 (CH2-2) and δH 2.30 (CH2-2′) were attributed to methylene groups
adjacent to two carbonyl groups (C-1 and C-1′, respectively). The remaining signals were assigned
with the aid of 2D NMR experiments. The COSY and the key HMBC correlations are depicted in
Figure 2. Briefly, the presence of a glycine moiety was supported by the observed COSY correlations
between the amide proton (Gly)NH at δH 6.38 and H2-2′ ′, as well as the HMBC correlations observed
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from H2-2′ ′ to both C-1′ ′ and C-1. The oxymethine H-3 scalarly coupled with two methylenes (δH 1.62,
2H, m, H-4; δH 2.54, 2H, m, H-2) in the COSY spectrum. The position C-3 was identified as the site of
esterification with a (lower) iso-fatty acyl moiety based on the HMBC correlation of H-3 with the ester
carbonyl at C-1′ plus the additional HMBC correlations, namely H2-2/C-3, H-3/C-1, H-3/C-2, H-3/C-4,
H2-2′/C-1′, and H-3′/C-1′. The MS/MS fragment ion at m/z [M + Na]+ 348.2515 (C19H35NO3Na)
corresponding to [M + Na−C14H28O2]+ allowed the identification of the (lower) iso-fatty acyl moiety
as 12-methyl-tridecanoic acid (=iso-tetradecanoic acid). Compound 1 is structurally identical with
compound 4, with the exception of the alkyl chain length of the (lower) fatty acyl portion, which is
iso-pentadecanoic acid in 4. Due to the complexity of H-3 signal in the 1H NMR spectrum, a coupling
constant (J) analysis was not possible, hence the stereochemical assignment of the C-3 was solely based
on its [α]D value. The positive sign of the specific rotation value ([α]
22
D + 45, CHCl3) and structural
analogy to the known compound 4 ([α]22D + 0.77, CHCl3) [15], it is biosynthetically reasonable to
assume that 1 has the same (R) configuration at C-3. Thus, the new compound 1 was identified as
R-(+)-N-[15-methyl-3-(12-methyltridecanoyloxy)-hexadecanoyl]glycine.









2 2.54, m 2.51, m 2.50, m
3 5.16, m 5.17, m 5.17, m
4 1.62 a 1.60, m 1.60, m
5 1.30 a 1.30 a 1.30 a
6–13 1.25 a 1.25 a 1.25 a
14 1.14, m 1.14, m 1.14, m
15 1.51, m 1.51, m 1.51, m
16 0.86, d (6.7) 0.86, d (6.7) 0.86, d (6.7)
17 0.86, d (6.7) 0.86, d (6.7) 0.86, d (6.7)
2′ 2.30, t (7.5) 2.34 a 2.37 a
3′ 1.60 a 2.34 a 2.36 a
4′ 1.28 a 5.30, m 5.30, m
5′ 1.25 a 5.40, m 5.42, m
6′ 1.25 a 2.02, m 2.04, m
7′ 1.25 a 1.33, m 1.33, m
8′–10′ 1.25 a 1.25, m 1.25, m
11′ 1.14, m 1.25 a 1.25 a
12′ 1.51, m 1.14, m 1.14, m
13′ 0.86, d (6.7) 1.51, m 1.51, m
14′ 0.86, d (6.7) 0.86, d (6.7) 0.86, d (6.7)
15′ 0.86, d (6.7) 0.86, d (6.7)
2′ ′ 4.07, d (5.0) 4.03, d (5.3) 4.03, d (5.3)
2′ ′ ′ 4.66, m
3′ ′ ′ 4.00
a
3.96 a
OCH3 3.75, s 3.75, s
(Gly)NH 6.38, brt (5.3) 6.25, brt (5.0) 6.38, t (4.5)
(Ser)NH 6.90, d (7.7)
a Overlapped with other signals.
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Table 2. 13C NMR data of compounds 1–3 (150 MHz, CDCl3).
Position
1 a 2 3
δC, Type δC, Type δC, Type
1 170.5, C 169.9, C 170.8, C
2 41.4, CH2 41.2, CH2 41.7, CH2
3 71.1, CH 71.3, CH 71.5, CH
4 34.1, CH2 34.3, CH2 34.2, CH2
5 25.4, CH2 29.5, CH2 29.6, CH2
6–13 29.0, CH2 29.0, CH2 29.0, CH2
14 39.1, CH2 39.1, CH2 39.1, CH2
15 27.8, CH 27.8, CH 27.8, CH
16 22.7, CH3 22.7, CH3 22.7, CH3
17 22.7, CH3 22.7, CH3 22.7, CH3
1′ 173.7, C 173.9, C 173.7, C
2′ 34.5, CH2 34.4, CH2 34.4, CH2
3′ 24.9, CH2 22.7, CH2 22.6, CH2
4′ 29.0, CH2 127.2, CH 127.1, CH
5′ 29.0, CH2 131.6, CH 131.7, CH
6′ 29.0, CH2 27.1, CH2 27.1, CH2
7′ 29.0, CH2 29.6, CH2 29.5, CH2
8′–10′ 29.0, CH2 29.0, CH2 29.0, CH2
11′ 39.1, CH2 29.0, CH2 29.0, CH2
12′ 27.8, CH 39.1, CH2 39.1, CH2
13′ 22.7, CH3 27.8, CH 27.8, CH
14′ 22.7, CH3 22.7, CH3 22.7, CH3
15′ 22.7, CH3 22.7, CH3
1′ ′ 171.1, C 170.2, C 170.0, C
2′ ′ 41.1, CH2 41.2, CH2 41.1, CH2
1′ ′ ′ 170.6, C
2′ ′ ′ 54.8, CH2
3′ ′ ′ 62.7, CH
OCH3 52.0, CH3 52.0, CH3
a Extracted from HSQC and HMBC spectra.
Figure 2. The COSY (in bold), key H→C HMBC (arrows) and H→H NOE (dashed line) correlations
observed for the new compounds 1 and 3.
The compound 2 (m/z [M + Na]+ 602.4767), also a yellow oil, was assigned the molecular
formula of C35H65NO5 by HRESIMS. Based on the comparison of its NMR and HRESIMS/MS data
with other purified compounds, 2 was identified as the methyl ester of the known compound 5.
The difference of 14 Da with the molecular formula of 5 (m/z [M + Na]+ 588.4617) indicated the
presence of a methyl ester function in 2. The detailed analysis of the 2D NMR spectra confirmed the
full spin system of the (lower) iso-fatty acyl moiety and the position of the double bond between C-4′
and C-5′. The key COSY correlations were observed between the olefinic protons H-4′ (δH 5.30) and
H-5′ (δH 5.40), as well as between H-4′ and H2-3′ (δH 2.34) and H-5′ and H2-6′ (δH 2.02). The diagnostic
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HMBC correlations were those between H2-3′/C-2′, H2-3′/C-1′ and H-5′/C-4′, H-5′/C-3′. The HMBC
cross peak between the methoxyl signal (δH 3.75 s) and C-1′ ′ (δC 170.2) confirmed the methylation
of the carboxylic acid of the N-terminal glycine residue (Figure 1). The complexity of the H-4′
and H-5′ refrained us doing coupling constant (J) analysis, but the clear NOE correlation between
H2-3′ and H2-6′ indicated the Z configuration of the double bond ∆4
′
. The analysis of the MS/MS
fragmentation pattern of 2 supported the assignment of the (lower) fatty acyl moiety, as in compounds
5–7, as iso-pentadecenoic acid (fragment ion at m/z [M + Na]+ 362.2674 corresponding to a loss of
240 Da equivalent to C15H28O2). The stereochemical configuration of the C-3 atom was assigned as R
based on the positive specific rotation value ([α]22D + 8.5, CHCl3), analogous to that of 5 ([α]
22
D + 0.45,
CHCl3) [15]. Since MeOH was never used in the extraction or in the isolation procedure and the
residual signal of the methoxyl group was visible in the 1H-NMR spectrum of the crude EtOAc extract,
compound 2 cannot be considered an artifact. Thus, the chemical structure of the new compound 2 is
R-(+)-N-[15-methyl-3-(13-methyl-4Z-tetradecenoyloxy)-hexadecanoyl]glycine methyl ester.
The molecular formula of compound 3 was established as C38H70N2O7 by HRESIMS (m/z
[M + Na]+ 689.5085). Based on the comparison of the NMR and HRESIMS/MS data, 3 was identified
as methyl ester of the known compound 7 ([M + Na]+ 675.4936, difference of 14 Da in their molecular
formulae). The N-terminal amino acid residue was identified as serine based on the 2D COSY
NMR spectrum that contained a short spin system including the amide proton (δH 6.90, 1H, d,
(Ser)NH), the diastereotopic methylene H2-3′ ′ ′ (δH 3.96, 1H, H-3′ ′ ′a; δH 4.00, 1H, H-3′ ′ ′b) and the
oxymethine H-2′ ′ ′ (δH 4.66, 1H, m). Figure 2 depicts the COSY as well as the key HMBC and NOESY
correlations observed for compound 3. Briefly key HMBC correlations observed for compound
3 include (Ser)NH/C-1′ ′ ′, OCH3/C-1′ ′ ′, H-2′ ′ ′/C-1′ ′’ and H2-3′ ′ ′/C-1′ ′ ′. The configuration of the
∆4
′
was assigned as Z based on the NOE correlation between H2-3′/H2-6′ (Figure 2). Similar to 7,
the MS/MS spectrum of 3 revealed a fragment at m/z [M + Na]+ 449.2977 due to loss of 240 Da
(C15H28O2) confirming the assignment of the (lower) fatty acyl moiety as iso-pentadecenoic acid.
Compound 3 has previously been synthetized by Uchida et al. (1985) starting from the aminolipid
named (3R, L-serine)-WB-3559B [18], but it has never been reported as a natural product before. Based
on (i) the strict biosynthetic relationship to the known compound 7 (ii) the fact that all serine residues
in WB3559 metabolites [17,18] have been reported with L-configuration, (iii) the positive optical
rotation value ([α]22D + 45, CHCl3) comparable to that of 7 ([α]
22
D + 16.7, CHCl3) [18], it is reasonable
to assume that 3 has the same (R) configuration at C-3 and contains L-serine as N-terminal amino
acid. Again, as we never used MeOH in the extraction or in the isolation procedure, compound 3
should be considered a genuine natural compound, and no artifact. Thus, the new compound 3 is
N-[N-[3(R)-15-methyl-3-(13-methyl-4Z-tetradecenoyloxy)-hexadecanoyl]glycyl]-L-serine methyl ester.
Compounds 1–7 were tested in vitro for their antimicrobial activity against MRSA. As shown in
Table 3, all four N-terminal glycine-containing aminolipids (1, 2, 4, 5) exhibited higher to equal activity
to the crude EtOAc extract (IC50 value 120 µg/mL). The IC50 values observed for each compound
were as follows: 1 (58 µg/mL), 2 (145 µg/mL), 4 (22 µg/mL) and 5 (93 µg/mL). These results indicate
that the methylation of the N-terminal amino acid residue or the introduction of a double bond in the
lower iso-fatty acyl chain diminishes or totally abolishes the antibiotic activity (IC50 > 200 µg/mL).
In addition, all N-terminal serine-bearing analogues (3, 6, 7) were devoid of any inhibitory potential
even at the highest test concentrations (200 µg/mL), suggesting that the glycine is the favoured
N-terminal amino acid.
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Table 3. In vitro anti-MRSA activity of the EtOAc pellet extract and compounds 1–7. Reference
drug: chloramphenicol.











Back in 1999, Batrakov et al. suggested the phosphorus-free lipoaminoacids to be widely
distributed among Gram-negative bacteria [16]. Indeed, the Gram-negative bacteria have frequently
been reported as producers of aminolipids [19–21] detected in complex total lipid fractions. However,
due to difficulties in their purification, they were mostly left as “unidentified aminolipids” without
further isolation or chemical characterization [22,23]. Only a few N-(β-acyloxyacyl) amino acids
have been reported from the Gram-negative order Flavobacteriales including the members of
the families Flavobacteriaceae (e.g., Flavobacterium sp.) and Cytophagaceae (e.g., Cytophaga and
Cyclobacterium sp.) [14–18]. They are often lipomonopeptides or lipodipeptides containing glycine,
serine, ornithine or glycyl-serine as amino acid residue and an iso-fatty acid ester at C-3 with
different degrees of unsaturation [15,16,18,24]. Ornithine and serine-containing (amino)lipids of some
Gram-negative pathogenic bacteria are known to hemagglutinate human and rabbit erythrocytes [25].
Fibrinolytic [17], macrophage activation [26], N-type calcium channel blockage [15] and biosurfactant
type activities [24,27] have also been reported for this chemical family. While some natural cyclic
aminolipids (short lipopeptides) have been shown to exert antibacterial effects [28], the only linear
aminolipids with demonstrated antibacterial activity are the synthetically prepared molecules,
e.g., N-stearoyl proline [29]. Hence, it appears that this is the first study reporting the antimicrobial
activity of linear aminolipids of bacterial origin. Odd-numbered fatty acids are frequent in bacteria
with C15:0, C17:0 or C19 lipids being the most common ones [30]. The isolation of mixed odd and even
iso-fatty acids, some as part of the same compound (e.g., compounds 1, 7), from bacteria is however
unusual. The HRMS2 data permitted to confirm and to highlight three types of (lower) fatty acyl
moieties (i.e., iso-tetradecanoic acid (1), iso-pentadecanoic acid (4), iso-pentadecenoic acid (2, 3, 5, 6, 7)
and in all seven compounds isolated. The chain length of the (upper) 3-hydroxy iso-fatty acid amide
was generally C17, except for the compound 6 (C16). These information combined with detailed NMR
data confirmed the compound identifications.
4. Materials and Methods
4.1. General Experimental Procedures
Optical rotation measurements were conducted on a Jasco P-2000 polarimeter (Jasco, Pfungstadt,
Germany). IR spectra were recorded on a PerkinElmer Spectrum Two FT-IR spectrometer (PerkinElmer,
Boston, MA, USA). NMR spectra were obtained on a Bruker AV 600 spectrometer (600 and 150 MHz for
1H and 13C NMR, respectively, Bruker®, Billerica, MA, USA) equipped with a Z-gradient triple
resonance cryo-probehead. The residual solvent signals of chloroform-d were used as internal
references (δH 7.26 and δC 77.2). High-resolution mass spectrometry and fragmentation data were
recorded using a Waters Xevo G2-XS QTof Mass Spectrometer (Waters®, Milford, MA, USA) coupled
to a Waters Acquity UPLC system (Waters®, Milford, MA, USA). Crude extract fractionation was
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performed using Chromabond SPE C18 column cartridges (Macherey-Nagel, Duren, Germany). HPLC
separations were performed on a VWR Hitachi Chromaster system (VWR International, Allison Park,
PA, USA) consisting of a 5430 diode array detector (VWR International, Allison Park, PA, USA), a 5310
column oven, a 5260 autosampler and a 5110 pump combined in parallel with a VWR Evaporative
Light Scattering Detector (ELSD 90, VWR International, Allison Park, PA, USA). The eluents used
for HPLC separations were H2O (A) and MeCN (B). Routine HPLC separations were performed on
semipreparative (Onyx, 10 mm × 100 mm, Phenomenex, Torrance, CA, USA) and analytic (Onyx,
3 mm × 100 mm, Phenomenex, Torrance, CA, USA) C18 Monolithic Phenomenex columns. MCC
culture chips (Elga Europe, Milan, Italy and Hoekmine BV, Utrecht, The Netherlands) were fabricated
as previously described using a photolithographic process to create 4500 microwells (180 µm diameter,
10 µm high walls) on a 36 mm × 8 mm (10 µm thick, pore size < 200 nm) wafer of porous aluminium
oxide (General Electric, Frankfurt am Main, Germany) [5,6].
4.2. Isolation and Identification of Biological Material
The shallow water (50 cm depth) sediments were collected by using sterile 50 mL Falcon tubes in
January 2014 during an expedition in the framework of National Program for Antarctic Research of
Italy (PNRA) in the area of Edmonson Point, Antarctica. The isolation of the bacterium from Antartic
sea sediment using the MCC will be described in detail in another communication. Briefly, the culture
chips were sterilized by high intensity UV treatment for 30 min and were then placed on the flat surface
of packed sediment in a Petri dish. Microcolonies growing after 1–3 weeks were recovered using a fine
toothpick and were suspended in 50 µL of sterile water. Half of the resuspended colony was stored at
−80 ◦C with 20% glycerol while the other half used to perform the identification via PCR of 16S rDNA
genes. PCR products were then purified, sequenced and submitted to BLAST for the phylogenetic
analysis. The 16S rRNA sequence of 1432 bp was compared to the NCBI nucleotide database by
using BLASTn. The closest relative type strain is Aequorivita antarctica strain SW49T/ACAM640T
(GenBank accession no: NR_025639.1), which shows a sequence similarity of 98% to our isolate and
was isolated from under-ice seawater in Prydz Bay, Antarctica [13]. The 16S sequence was deposited
in GenBank (accession number MH012204). A voucher specimen (23L) is housed at Institute of Protein
Biochemistry, National Research Council, Italy.
4.3. Fermentation, Extraction and Isolation
Large-scale culture (10 L) was performed cultivating Aequorivita sp. in Marine Broth medium
(DifcoTM, Eysins, Switzerland) for 5 days at 20 ◦C at 200 rpm. The culture was centrifuged and
pellet and supernatant were separately extracted with EtOAc. The EtOAc extract of the pellet was
evaporated to dryness under vacuum, yielding 800 mg of dry residue. The crude EtOAc extract
(380 mg) that showed moderate anti-MRSA activity was fractionated on a Chromabond SPE C18
cartridge. The elution with a 25% gradient of MeCN afforded 6 fractions. Anti-MRSA activity was
tracked to fractions 5 (5 mg) and 6 (241 mg). Due to the low amounts of fraction 5, only the SPE fraction
6 was worked-up. This fraction was subjected to semi-prep. RP-HPLC chromatography (gradient
of H2O:MeCN from 50:50 to 0:100 in 27 min, flow 4.0 mL/min) to yield compounds 6 (1.7 mg, tR
21.8 min) and 7 (1.7 mg, tR 22.6 min), along with other five fractions (A–E). The fraction A (7 mg) was
then chromatographed a second time by RP-HPLC (isocratic mixture H2O:MeCN 1:9 in 10 min, flow
1.0 mL/min) to yield 3 (1.0 mg, tR 7.0 min) in a pure state. The fraction B (6 mg) was further purified
by RP-HPLC (isocratic mixture H2O:MeCN 1:9 in 10 min, flow 1.0 mL/min) to give 5 (1.0 mg, tR
7.3 min) and 1 (1.5 mg, tR 8.2 min). The purification of the fraction C (5.6 mg) under the same RP-HPLC
conditions afforded 2 (4.0 mg, tR 10 min). Finally, the fraction D (3 mg) was rechromatographed by
RP-HPLC (gradient of H2O:MeCN from 50:50 to 0:100 in 8 min, flow 1.0 mL/min) affording 4 (1.0 mg,
tR 10 min).
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4.4. LC-HRMS2
Experiments were performed using a Waters Xevo G2-XS QTof Mass Spectrometer coupled to
a Waters Acquity UPLC I-Class system. The LC-MS analysis was performed using an Acquity UPLC
HSS T3 column (High Strength Silica C18, 1.8 µm, 2.1 mm × 100 mm, Waters®, Milford, MA, USA),
maintained at 40 ◦C, operating a linear gradient H2O:MeCN (both containing 0.1% of formic acid)
from 1% MeCN to 100% MeCN over 15 min, keeping 100% MeCN for 3 min and reconditioning of
the column during 3 min (flow rate 0.6 mL/min). All the high-resolution mass spectra were recorded
in the positive-ion mode in a mass range from m/z 50 to 1600. MS parameters were: spray voltage
of 0.8 kV, source temperature 150 ◦C, desolvation temperature 650 ◦C, cone gas flow 50 L/Hr and
desolvation gas flow 1200 L/Hr. Data were collected in the data-dependent acquisition (DDA) mode
and targeted MS/MS acquisition mode was performed for each pure compounds isolated. A collision
energy ramp from 30 to 80 eV was applied. Acquisition and data analyses were carried out with
the MassLynx software (version 4.1, Waters®, Milford, MA, USA). Multiple commercial and public
databases (MarinLit, Dictionary of Natural Products, PubChem, Chemspider, Raleigh, NC, USA) were
used for dereplication and annotation of known compounds.
R-(+)-N-[15-methyl-3-(12-methyltridecanoyloxy)-hexadecanoyl]glycine (1): yellow oil; [α]22D +45 (c 1.3,
CHCl3); IR (film) vmax 3329, 2923, 2853, 1731, 1649, 1465, 1179 cm−1; 1H NMR (CDCl3, 600 MHz) and
13C NMR (CDCl3, 150 MHz) Tables 1 and 2; HRESIMS found m/z [M + Na]+ 576.4603; C33H63NO5Na,
requires 576.4604.
R-(+)-N-[15-methyl-3-(13-methyl-4Z-tetradecenoyloxy)-hexadecanoyl]glycine methyl ester (2): yellow oil;
[α]22D +8.5 (c 1.3, CHCl3); IR (film) vmax 3386, 2924, 2853, 1733, 1645, 1466, 1202 cm
−1; 1H NMR (CDCl3,
600 MHz) and 13C NMR (CDCl3, 150 MHz) Tables 1 and 2; HRESIMS found m/z [M + Na]+ 602.4767;
C35H65NO5Na requires 602.4760.
N-[N-[3R-15-methyl-3-(13-methyl-4Z-tetradecenoyloxy)-hexadecanoyl]glycyl]-L-serine methyl ester (3):
yellow oil; [α]22D +45 (c 1.3, CHCl3); IR (film) vmax 3360, 2923, 2853, 1734, 1657, 1544, 1465, 1366,
1205, 1177, 1035 cm−1; 1H NMR (CDCl3, 600 MHz) and 13C NMR (CDCl3, 150 MHz) Tables 1 and 2;
HRESIMS found m/z [M + Na]+ 689.5085; C38H70N2O7Na requires 689.5081.
4.5. Anti-MRSA Assay
Antibacterial assay was performed using the clinically relevant bacterial test strain
Staphylococcus aureus (methillicin-resistant, DSM 18827). It was cultivated in Trypticase soy broth
(1.2% Trypticase soy broth, 0.5% NaCl) overnight and diluted to an OD600 of 0.01. 40 mg mL−1 DMSO
stock solution of the compound was diluted with medium to gain the desired test concentrations.
In addition, 10.5 µL of the compound solution and 200 µL of the test strain cell suspension were
transferred in a 96-well microtiter plate and incubated for 5 h at 37 ◦C and 200 rpm. After the
addition of 10 µL of a resazurin solution as the detective reagent (0.3 mg mL−1 in phosphate-buffered
saline), the incubation was continued for another 5 min. To evaluate cell viability, the reduction of
resazurin to resorufin was determined by measuring the intensity of fluorescence at 560Ex/590Em
in a Tecan Infinite M200 plate reader (Männedorf, Switzerland). The IC50 values were calculated by
Excel (version 2013, Microsoft, Redmond, Washington, DC, USA) as the concentration that showed
50% inhibition of viability on the basis of a negative control (no compound). Chloramphenicol was
used as a positive control.
5. Conclusions
In summary, LC-MS2-based dereplication in combination with a traditional MRSA-activity guided
fractionation allowed the accelerated work-up of the Antarctic Gram-negative bacterium Aequorivita
sp. that was rapidly isolated by an innovative culture chip technique. We report herein the isolation,
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structural elucidation and moderate antimicrobial activity of natural linear aminolipids. This is the
first chemical and bioactivity study performed on an Aequorivita species.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/16/6/187/s1,
NMR, HRESIMS and MS/MS spectra of compounds 1–3, and HRESI-MS/MS spectra of the known compounds
4–7.
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